Category: St. Jude Medical
The top three medical device stories for November 21, 2011.
Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This latest feature of MassDevice.com's coverage highlights our three biggest and most influential stories from the day's news to make sure you're up to date on the headlines that continue to shape the medical device industry.
If you read nothing else today, make sure you're still in the know with MassDevice +3.
Results from St. Jude's study of its Libra deep brain stimulator show reduced symptoms among patients suffering from highly treatment-resistant depression.
St. Jude Medical's (NYSE:STJ) deep brain stimulation implant proved safe and effective in treatment of patients with severe therapy-resistant depression.
Results from the first multi-center pilot study, conducted among 21 patients, found that 62 percent reported a 40 percent reduction in depression symptoms and 29 percent reported that their symptoms were cut in half after one year.
Results from the first multi-center pilot study of deep brain stimulation (DBS) for major depressive disorder were published online today by the Journal of Neurosurgery. The study, conducted at three research facilities in Canada, was designed to replicate and build upon an earlier study by Dr. Andres Lozano and Dr. Helen Mayberg which was published in the journal Neuron in 2005. Sponsored by St. Jude Medical, Inc. (NYSE:STJ), the study demonstrates significant improvement in depression symptoms among patients who are highly treatment resistant.
The top seven medical device stories for the week of November 17, 2011.
Say hello to MassDevice +7, a bite-sized view of the top seven med-tech stories of the week. This latest feature of MassDevice.com's coverage highlights our seven biggest and most influential stories from the week's news to make sure you're up to date on the headlines that continue to shape the medical device industry.
If you read nothing else this weekend, make sure you're still in the know with MassDevice +7.
Patients treated with Edwards Lifesciences' Sapien heart valve have lower mortality rates and spend less time in hospitals at two years, according to data released at this year's Transcatheter Cardiovascular Therapeutics symposium.
Patients treated with Edwards Lifesciences' (NYSE:EW) Sapien heart valve had a lower mortality rate and spent less time in hospitals at the two-year mark, according to the data released at this year's Transcatheter Cardiovascular Therapeutics symposium.
The Partner trial consisted of patients with aortic stenosis, randomized to receive a Sapien valve with transcatheter aortic valve replacement surgery or traditional open-heart surgery.
A federal judge in Arkansas rules that a St. Jude Medical patent covering vascular closure technologies is protected from a challenge by Access Closure Inc., even though it's similar enough to another St. Jude patent to be deemed invalid.
A federal judge sided with St. Jude Medical (NYSE:STJ) in a patent infringement dispute with Access Closure Inc. over technologies used to close holes in arteries.
Philips agrees to offer St. Jude Medical's PressureWire Aeris fractional flow reserve measurement device along with its Xper Flex Cardio physiomonitoring system.
St. Jude Medical (NYSE:STJ) inked a deal to have its PressureWire Aeris fractional flow reserve technology offered with Philips' (NYSE:PHG) Xper Flex Cardio physiomonitoring system.
FFR is a measurement of the severity of coronary artery blockage. St. Jude's wireless device links with cardiac catheterization lab systems to track and log FFR measurements during coronary intervention procedures such as angiography.